Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

RK Asset Management boosted its stake in Regeneron Pharmaceuticals by 25.8%, bringing its total to 12,563 shares worth $7.97 ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Nvidia falls after rallying Thursday, Marvell’s latest earnings fail to impress Wall Street, and Gap and American Eagle ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

DSG Capital Advisors bought 847 Regeneron shares, valuing their stake at around $603,000, joining a long list of eager ...